---
title: "Adhera Therapeutics, Inc. (ATRX.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/ATRX.US.md"
symbol: "ATRX.US"
name: "Adhera Therapeutics, Inc."
industry: "Biotechnology"
datetime: "2026-05-20T04:11:55.695Z"
locales:
  - [en](https://longbridge.com/en/quote/ATRX.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/ATRX.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/ATRX.US.md)
---

# Adhera Therapeutics, Inc. (ATRX.US)

## Company Overview

Adhera Therapeutics, Inc., a biotech company, focuses on the discovery, development, and commercialization of small molecule drugs. The company is developing MLR-1019 for the treatment of Parkinson’s disease; and MLR -1023 to treat Type 1 diabetes. The company was formerly known as Marina Biotech, Inc. and changed its name to Adhera Therapeutics, Inc.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [adherathera.com](https://adherathera.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: 
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 1970-01-01T00:00:00.000Z

**Overall:  (0.00)**

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| Dividend Yield | 0.00% | - | - | - | - |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/ATRX.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/ATRX.US/norm.md)
- [Related News](https://longbridge.com/en/quote/ATRX.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/ATRX.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**